National Human Genome Research Institute (NHGRI)
Open enrollment with an early-phase pipeline tilt
According to ClinicalTrials.gov-derived indexes, National Human Genome Research Institute (NHGRI) sits in the top decile of US sponsors by registered trial count (#161 of 15,742 sponsors by registered trial count).
National Human Genome Research Institute (NHGRI): 185 sponsored US clinical trials, 30 recruiting.
National Human Genome Research Institute (NHGRI) sponsors 185 registered US clinical trials on ClinicalTrials.gov, 30 of them currently recruiting, and 143 completed. 0 of these trials are in Phase 3-4 (later-stage) and 18 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is Proteus Syndrome, with 3 trials.
Top-decile sponsor footprint
National Human Genome Research Institute (NHGRI) ranks in the top decile of sponsors by registered trial count (#161 of 15,742 sponsors by registered trial count). Volume at this scale usually reflects a long institutional pipeline, read phase tilt and therapeutic areas below before treating it as current-year activity.
Trial completion reliability score
143 of 152 decided trials (Completed vs. Terminated on ClinicalTrials.gov) reached their planned completion (94.1%), vs. national p10 68.4% / p90 100% among 1,234 sponsors with at least 10 decided trials. Still-open trials (Recruiting, Active-not-recruiting, Not-yet-recruiting) are excluded since they have not reached an outcome yet.
Open and recent trials
185 total, page 3 of 4
A Study of the Genetic Analysis of Brain Disorders
NCT00645645
Screening Behavior in Adults With Hereditary Hemorrhagic Telangiectasia
NCT00684879
Adaptation and Quality of Life Among Adults With Neurofibromatosis Type I
NCT00684398
The Experience of Caregivers of Children With Down Syndrome
NCT00695695
Patient Provider Communication and Interaction in a Virtual Clinical Setting
NCT00669188
Making Sense of a Positive Genetic Test Result for Huntington Disease
NCT00539747
Informed Choice Regarding Invasive Prenatal Testing
NCT00514553
Treatment Strategies for Children With Smith-Magenis Syndrome
NCT00506259
Predictors of Caregiver Adaptation to Pervasive Developmental Disorders
NCT00496210
Individuals Patterns of Disclosure About Huntington s Disease (HD) and the Association With Adaptation to HD
NCT00491842
African American Families and Lung Cancer Study
NCT00487760
Disclosing a Cystic Fibrosis Diagnosis to a Dating Partner
NCT00485082
Risk Communication Within Mexican-American Families
NCT00469339
Pilot Study of a Multi-Drug Regimen for Severe Pulmonary Fibrosis in Hermansky-Pudlak Syndrome
NCT00467831
Interventions to Educate An Underserved Population About Inherited Disease Risks
NCT00441077
Genetic Counselors' Experiences of Moral Value Conflicts With Clients
NCT00360711
Positron Emission Tomography (PET) Imaging in People With Gaucher Mutations
NCT00302146
Patients' Perspectives on Identity, Ancestry and Genetics
NCT00359710
Use of Virtual Reality to Communicate Concepts of Genomics to the General Public
NCT00316056
Invasive Prenatal Testing Decisions in Pregnancy After Infertility
NCT00341822
Experiences of Genetics Patients With Visible Abnormalities Who Facilitate Teaching in Genetics Clinics
NCT00341718
Perspectives of Individuals With Bipolar Disorder and Siblings of Individuals With Bipolar Disorder; A Telephone Interview Study
NCT00300820
Psychosocial Aspects of Genetic Testing for Hereditary Nonpolyposis Colon Cancer
NCT00341575
Intravenous Immune Globulin to Treat Hereditary Inclusion Body Myopathy
NCT00195637
Physicians' Understanding of Human Genetic Variation
NCT00339924
Positive Exposure: A Photography and Video Intervention for Individuals With Craniofacial Differences
NCT00340964
Developing Newborn Screening for Infants With Primary Immunodeficiency
NCT00113464
Clinical Study of Muenke Syndrome (FGFR3-Related Craniosynostosis)
NCT00106977
Analysis of Data From the Women's Contraceptive and Reproductive Experiences (CARE) Study
NCT00341159
Genetic Analysis of Craniofrontonasal Syndrome
NCT00339846
Genetic Analysis of Craniosynostosis, Philadelphia Type
NCT00367796
Long-Term Study of Nitisinone to Treat Alkaptonuria
NCT00107783
Prevalence of Ambivalence Regarding Prenatal Testing
NCT00342069
Impact of Lung Cancer Diagnosis on Relatives' Understanding of Genetic Risk and Receptivity to Quit Smoking
NCT00341341
Clinical Integration of Genetic Risk Assessment in Family Medicine
NCT00339794
Identification of Prostate Cancer Genes
NCT00342784
Clinical Studies of Progeria
NCT00094393
Study of Megakaryocytes From Patients With Abnormal Platelet Vesicles
NCT00086476
Genetics and Clinical Characteristics of Bardet-Biedl Syndrome
NCT00078091
Genetic Studies in the Amish and Mennonites
NCT00359580
Clinical and Genetic Studies on Holoprosencephaly
NCT00088426
Cell Studies of Parkinson's Disease
NCT00076505
Genetic Studies of Inflammatory Bowel Disease
NCT00340444
Genetic Analysis of Gray Platelet Syndrome
NCT00069680
Genetic Epidemiology of Lung Cancer
NCT00341835
The Value of Genetic Information to Adult Adopted Individuals
NCT00057694
Clinical and Molecular Investigations Into Ciliopathies
NCT00068224
Transitional Life Events in Patients With Friedreich's Ataxia: Implications for Genetic Counseling
NCT00056186
Family Studies of Eye Traits
NCT00342342
Pilot Study of the Process of Prenatal Genetic Counseling
NCT00047905
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 11 |
| Phase 2 | 7 |
Therapeutic Areas
What is open in the National Human Genome Research Institute (NHGRI) pipeline
30 recruiting of 185 indexed (16% open); 143 completed (77%).
Phase mix: 0 late (III/IV) vs 18 early (I/II) (early-phase heavy).
Top condition: Proteus Syndrome (3 trials), 9 others listed.
How open-pipeline share is computed
Recruiting share is recruiting_count divided by trial_count for this sponsor in the public registry export. Status can change between pulls; treat the figure as a research-attention snapshot, not product availability.
National Human Genome Research Institute (NHGRI): open-pipeline peers nationwide
Peers matched on 185 registered trials and 16% open enrollment, not the therapeutic-area sidebar.
National Human Genome Research Institute (NHGRI) sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together.
Sponsors near 185 trials (± recruiting share)
- Boston University · 185 trials · 12% recruiting
- Children's Mercy Hospital Kansas City · 184 trials · 11% recruiting
- Arizona State University · 187 trials · 15% recruiting
- Johns Hopkins Bloomberg School of Public Health · 187 trials · 14% recruiting
Sponsors near 16% open enrollment (± trial volume)
- BioMarin Pharmaceutical · 16% recruiting · 80 trials
- Atlantic Health System · 16% recruiting · 43 trials
- Drexel University · 16% recruiting · 92 trials
- Case Western Reserve University · 16% recruiting · 141 trials
Related
What to do with this National Human Genome Research Institute (NHGRI) page
185 registered trials is a research-attention snapshot, not an endorsement of National Human Genome Research Institute (NHGRI) or any single study.
- 30 of National Human Genome Research Institute (NHGRI)'s trials are currently recruiting, check each one's own eligibility criteria before contacting a site. Browse recruiting trials
- Proteus Syndrome is the condition National Human Genome Research Institute (NHGRI) studies most, compare against other sponsors active in the same condition before evaluating a specific study. See Proteus Syndrome trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
National Human Genome Research Institute (NHGRI) pipeline card: 185 registered trials from official public datasets.Report a data error.